James Ward-Lilley had a 28-year global pharmaceutical career at AstraZeneca before becoming chief executive of Vectura Group in September 2015 from June 2019. At Vectura, he was responsible for leading the business through a period including the merger with Skye pharma. At AstraZeneca, he held a number of senior roles including as regional vice president for Central Eastern Europe and the Middle East; led the respiratory, inflammation & autoimmunity franchise with responsibility for the revitalisation of one of AstraZeneca's three therapeutic areas including the acquisitions of Almirall's respiratory business and Pearl Therapeutics; and was responsible for leading its corporate device strategy in 2014/15 and sponsor for its initial investment in Adherium at the time of the IPO in 2015.
Mr Ward-Lilley has been the chief commercial officer of UK-based Aerogen Group since July 2020, and a director of its subsidiary Aerogen Pharma.
